Use of angiotensin II type 2 receptor agonist

US11123329B1 · kind B1 · utility

Assignee

• VICORE PHARMA AB · SE

Inventors

• Carl-Johan Dalsgaard · Stockholm, SE
• Johan Raud · Stockholm, SE
• Rohit Batta · Chino, US

Key dates

• Filing date: Dec 7, 2020
• Grant date: Sep 21, 2021
• Expiry date: Dec 7, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.